Clinical Trial

A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 16, 2026 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).
Protocol Amendment History 1 change
notable Trial sites expanded: 14 -> 24 locations 2026-04-17
Trial Details
NCT Number NCT07096674
Lead Sponsor Centessa Pharmaceuticals (UK) Limited
Conditions Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Enrollment 90 participants
Start Date 2025-08-12
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-16